Oxford Biomedica to manufacture vectors for Boehringer Ingelheim

By The Science Advisory Board staff writers

April 6, 2021 -- Oxford Biomedica has signed a three-year deal to manufacture and supply various types of viral vectors to Boehringer Ingelheim.

Under the terms of the development and supply agreement, Oxford Biomedica said it intends to manufacture good manufacturing practice (GMP) batches for Boehringer Ingelheim to support the development of viral vectors. The agreement also allows for Oxford Biomedica to manufacture and supply viral vectors in the future, according to the company.

Oxford Biomedica and its subsidiaries have built LentiVector, a lentiviral vector delivery platform that they use to develop in vivo and ex vivo products both internally and with partners.

Boehringer Ingelheim, Cure Genetics to develop novel AAV
Cure Genetics will collaborate with Boehringer Ingelheim to develop novel adeno-associated virus (AAV) vectors leveraging Cure Genetics' proprietary Velp...
Boehringer Ingelheim, Oxford BioTherapeutics partner further on antibodies
Boehringer Ingelheim and Oxford BioTherapeutics are partnering to discover novel targets for cancer immunotherapies using the Oxford Genome Anatomy Project's...
Boehringer Ingelheim acquires Northern Biologics
Boehringer Ingelheim on May 14 announced the acquisition of Northern Biologics, including its preclinical cancer antibody pipeline.
Boehringer Ingelheim expands COVID-19 collaborations
Boehringer Ingelheim announced that it is significantly increasing support for the fight against COVID-19, particularly by adding a number of strategic...
AACR launches $36M genomics project with big pharma
The American Association for Cancer Research (AACR) is launching a $36 million research project in collaboration with big pharma to expand its Genomics...

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter